The serum levels of CA125 was significantly higher in ovarian cancer patients than that in healthy individuals and benign patients, while the levels of transthyretin and apolipoprotein A1 were lower in ovarian cancer patients (Fig. 1A). This evidence concerns the gene APOA1 and ovarian cancer.